ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A Novel Prognostic Score Including the CD4/CD8 for AIDS-Related Lymphoma

Chen, Juanjuan*; Liu, Xuewu; Qin, Shanfang; Ruan, Guangjing; Lu, Aili; Zhang, Jinxin; Wu, Yihua; Xie, Zhiman*; Peng, Jie*南方医科大学
Frontiers in Cellular and Infection Microbiology2022-7-6DOI: 10.3389/fcimb.2022.919446
1被引5阅读
引用收藏
分享

摘要

BackgroundA simple and clinically applicable prognostic scoring system for AIDS-related lymphoma (ARL) in the era of combination antiretroviral therapy (cART) is needed to better stratify patients' risks and to assist in the decision-making of therapeutic strategies. MethodsWe conducted a retrospective multicenter cohort study in 138 primary ARL patients over an 8-year period from 2013 to 2020. Survival curves were estimated using the Kaplan-Meier method. Univariate and multivariate Cox proportional hazard models were performed to identify the association between patient-, lymphoma-, and HIV-specific variables with progression-free survival (PFS) and overall survival (OS). The incremental prognostic value of novel inflammatory biomarkers in the International Prognostic Index (IPI) was evaluated by comparing the receiver operating characteristic (ROC) curves, the concordance index (C-index), and the integrated Brier score (IBS). ResultsThe median age was 49.14 +/- 14.20 (range 18-79) years, 81.9% were men, and the median follow-up was 44.94 (95% CI = 37.05-52.84) months. The 3-year OS and PFS were 39.4% (95% CI = 16.3-21.2) and 38.7% (95% CI = 14.5-19.7), respectively. We found that age, extranodal sites, bulky mass, CD4 T-cell counts, CD4/CD8 ratio, and hypoalbuminemia were associated with OS (all P < 0.05) at both univariate and multivariate analyses. Of the new inflammatory markers, only the CD4/CD8 ratio was an independent prognostic parameter of OS and PFS. A lower CD4/CD8 ratio was strongly associated with adverse clinical factors, including older age, advanced Ann Arbor stage, more extranodal sites, elevated erythrocyte sedimentation rate, prior history of HIV, higher red cell distribution width ratio, hypoproteinemia, and emaciation. When the CD4/CD8 ratio was added to the IPI, the composite HIV-IPI score showed significantly better discrimination than IPI alone [AUC (95% CI): HIV-IPI, 0.83 (0.77-0.89) vs. IPI, 0.72 (0.70-0.85)]. The HIV-IPI model provided good predictive performance [C-index (95% CI): HIV-IPI, 0.82 (0.81-0.83) vs. IPI, 0.75 (0.73-0.77), P < 0.001] and a satisfactory calibration function. ConclusionsThe CD4/CD8 ratio, an inexpensive and readily available marker, is a powerful independent prognostic parameter in patients with ARL. Furthermore, when the CD4/CD8 ratio is used in combination with IPI, it increases prognostic ability. The useful prediction of expected outcomes in ARL can inform treatment decisions.

学科与关键词

关键词
AIDS-related lymphomasCD4CD8 rationovel prognostic scoreindependent prognostic parameterinflammatory marker
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Cellular and Infection Microbiology
发表日期
2022-07-06
卷期
第 12 卷
页码
919446
DOI
10.3389/fcimb.2022.919446
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81971949, 82071354]; Clinical Research Program of Nanfang Hospital, Southern Medical University [2018CR026]; Natural Science Foundation of Guangdong Province [2018A030313571]; Major Science and Technology Special Project of Nanning [20193008]

作者

  • C

    Chen, Juanjuan (通讯) (第一作者)

    southern med univ

  • L

    Liu, Xuewu

    southern med univ

查看全部 9 位作者收起作者
  • Q

    Qin, Shanfang

    hosp guangxi zhuang autonomous reg

  • R

    Ruan, Guangjing

  • L

    Lu, Aili

    southern med univ

  • Z

    Zhang, Jinxin

    southern med univ

  • W

    Wu, Yihua

    southern med univ

  • X

    Xie, Zhiman (通讯)

  • P

    Peng, Jie (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417